Randomized Trial of High Dose Influenza Vaccine in Long Term Care Setting
Status: | Completed |
---|---|
Conditions: | Influenza |
Therapuetic Areas: | Immunology / Infectious Diseases |
Healthy: | No |
Age Range: | 65 - Any |
Updated: | 4/21/2016 |
Start Date: | November 2011 |
End Date: | June 2014 |
The purpose of the study is to compare the performance of two currently available influenza
(flu) vaccines. This study will try and determine if the high dose flu vaccine provides
protection that is the same or better than that of regular dose flu vaccine. Both the
regular dose and the high dose flu vaccines are approved by the FDA for use in older adults.
(flu) vaccines. This study will try and determine if the high dose flu vaccine provides
protection that is the same or better than that of regular dose flu vaccine. Both the
regular dose and the high dose flu vaccines are approved by the FDA for use in older adults.
Influenza and pneumonia are the fifth leading cause of death in the United States, the
leading cause of vaccine preventable death, and the leading cause of infection related
deaths among nursing home residents(Nace, Drinka et al.2010). Each year, an estimated 36,000
individuals die from seasonal influenza and over 90% of these deaths occur among older
adults, primarily the frail older adults residing in LTC settings(Fiore,Uyeki et al.
2010).Vaccination is the most effective means of preventing influenza (Nichol and Treanor
2006). Despite increasing success in immunizing LTC residents though, outbreaks continue to
occur annually with case fatality rates ranging between 5-55% (Nace 2008). Older adults have
a reduced response to influenza vaccination, in part due to age related immunosenescence
(Keitel, Atmar et al. 1121; Skowronski, Tweed et al. 2008). It is widely recognized that
more effective vaccine options are needed for frail older adults. One option is to increase
the hemagglutinin (HA) dose in influenza vaccines in an effort to increase antibodies to
hemagglutinin. To date, no studies have evaluated the effectiveness of the HDIV among LTC
residents.
leading cause of vaccine preventable death, and the leading cause of infection related
deaths among nursing home residents(Nace, Drinka et al.2010). Each year, an estimated 36,000
individuals die from seasonal influenza and over 90% of these deaths occur among older
adults, primarily the frail older adults residing in LTC settings(Fiore,Uyeki et al.
2010).Vaccination is the most effective means of preventing influenza (Nichol and Treanor
2006). Despite increasing success in immunizing LTC residents though, outbreaks continue to
occur annually with case fatality rates ranging between 5-55% (Nace 2008). Older adults have
a reduced response to influenza vaccination, in part due to age related immunosenescence
(Keitel, Atmar et al. 1121; Skowronski, Tweed et al. 2008). It is widely recognized that
more effective vaccine options are needed for frail older adults. One option is to increase
the hemagglutinin (HA) dose in influenza vaccines in an effort to increase antibodies to
hemagglutinin. To date, no studies have evaluated the effectiveness of the HDIV among LTC
residents.
Inclusion Criteria:
- Residents of one of the participating LTC sites
- 65 years or older at the time of consent
- require assistance in two or more Instrumental Activities of Daily Living and/or one
or more Activities of Daily Living as identified by facility staff
Exclusion Criteria:
- Age less than 65 years
- Life expectancy less than 6 months
- History of allergic reaction to influenza vaccine, its components, or eggs
- History of severe allergic reaction to latex
- History of Guillian-Barre Syndrome
- Actively undergoing chemotherapy
- Actively undergoing radiation therapy
- Use of prednisone (or other steroid) at prednisone-equivalent dosages of 10mg or
higher within the past 14 days
- Serious current immunosuppression or immunosuppression expected in the next 6 weeks
- Any condition that, in the opinion of the investigator,might interfere with the
evaluation of study objectives
We found this trial at
1
site
Click here to add this to my saved trials